Screener
Veracyte VCYT Sales & Marketing
Sales & Marketing at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Gross profit | 101,159 | 79,508 |
| Operating expenses: | ||
| Research and development | 27,098 | 17,720 |
| Selling and marketing | 27,156 | 24,454 |
| General and administrative | 23,680 | 33,808 |
| Intangible asset amortization - operating expenses | 579 | 622 |
| Total operating expenses | 78,513 | 76,604 |
| Income from operations | 22,646 | 2,904 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's sales & marketing?
- Veracyte (VCYT) reported sales & marketing of $27.16M in Q1 2026.
- How has Veracyte's sales & marketing changed year-over-year?
- Veracyte's sales & marketing increased by 11.0% year-over-year, from $24.45M to $27.16M.
- What is the long-term trend for Veracyte's sales & marketing?
- Over 4 years (2021 to 2025), Veracyte's sales & marketing has grown at a 5.8% compound annual growth rate (CAGR), from $79.84M to $100.17M.
- What does sales & marketing mean?
- Costs of selling products and services including sales force compensation, commissions, marketing campaigns, trade shows, and customer acquisition expenses.
Ask your AI about Veracyte's sales & marketing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude